Literature DB >> 31439150

Common characteristics and unique features: A comparison of the fusion machinery of the alphaherpesviruses Pseudorabies virus and Herpes simplex virus.

Melina Vallbracht1, Marija Backovic2, Barbara G Klupp3, Felix A Rey2, Thomas C Mettenleiter3.   

Abstract

Membrane fusion is a fundamental biological process that allows different cellular compartments delimited by a lipid membrane to release or exchange their respective contents. Similarly, enveloped viruses such as alphaherpesviruses exploit membrane fusion to enter and infect their host cells. For infectious entry the prototypic human Herpes simplex viruses 1 and 2 (HSV-1 and -2, collectively termed HSVs) and the porcine Pseudorabies virus (PrV) utilize four different essential envelope glycoproteins (g): the bona fide fusion protein gB and the regulatory heterodimeric gH/gL complex that constitute the "core fusion machinery" conserved in all members of the Herpesviridae; and the subfamily specific receptor binding protein gD. These four components mediate attachment and fusion of the virion envelope with the host cell plasma membrane through a tightly regulated sequential activation process. Although PrV and the HSVs are closely related and employ the same set of glycoproteins for entry, they show remarkable differences in the requirements for fusion. Whereas the HSVs strictly require all four components for membrane fusion, PrV can mediate cell-cell fusion without gD. Moreover, in contrast to the HSVs, PrV provides a unique opportunity for reversion analyses of gL-negative mutants by serial cell culture passaging, due to a limited cell-cell spread capacity of gL-negative PrV not observed in the HSVs. This allows a more direct analysis of the function of gH/gL during membrane fusion. Unraveling the molecular mechanism of herpesvirus fusion has been a goal of fundamental research for years, and yet important mechanistic details remain to be uncovered. Nevertheless, the elucidation of the crystal structures of all key players involved in PrV and HSV membrane fusion, coupled with a wealth of functional data, has shed some light on this complex puzzle. In this review, we summarize and discuss the contemporary knowledge on the molecular mechanism of entry and membrane fusion utilized by the alphaherpesvirus PrV, and highlight similarities but also remarkable differences in the requirements for fusion between PrV and the HSVs.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alphaherpesvirus entry and fusion; Cell-to-cell spread; Core fusion machinery; Glycoproteins gD; Herpes simplex virus HSV; In vitro fusion; Membrane fusion; Prefusion gB; Pseudorabies virus PrV; Virus entry; gB and gH/gL

Mesh:

Substances:

Year:  2019        PMID: 31439150     DOI: 10.1016/bs.aivir.2019.05.007

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  13 in total

1.  Using Split Luciferase Assay and anti-HSV Glycoprotein Monoclonal Antibodies to Predict a Functional Binding Site Between gD and gH/gL.

Authors:  Doina Atanasiu; Wan Ting Saw; Tina M Cairns; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2021-01-27       Impact factor: 5.103

2.  Localization of the Interaction Site of Herpes Simplex Virus Glycoprotein D (gD) on the Membrane Fusion Regulator, gH/gL.

Authors:  Tina M Cairns; Doina Atanasiu; Wan Ting Saw; Huan Lou; J Charles Whitbeck; Noah T Ditto; Birgitte Bruun; Helena Browne; Lucas Bennett; Chun Wu; Claude Krummenacher; Benjamin D Brooks; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

Review 3.  The structural basis of herpesvirus entry.

Authors:  Sarah A Connolly; Theodore S Jardetzky; Richard Longnecker
Journal:  Nat Rev Microbiol       Date:  2020-10-21       Impact factor: 60.633

4.  Influence of N-glycosylation on Expression and Function of Pseudorabies Virus Glycoprotein gB.

Authors:  Melina Vallbracht; Barbara G Klupp; Thomas C Mettenleiter
Journal:  Pathogens       Date:  2021-01-12

5.  Alphaherpesvirus-induced activation of plasmacytoid dendritic cells depends on the viral glycoprotein gD and is inhibited by non-infectious light particles.

Authors:  Jonas L Delva; Cliff Van Waesberghe; Barbara G Klupp; Thomas C Mettenleiter; Herman W Favoreel
Journal:  PLoS Pathog       Date:  2021-11-29       Impact factor: 6.823

6.  A Genome-Wide CRISPR/Cas9 Screen Reveals the Requirement of Host Sphingomyelin Synthase 1 for Infection with Pseudorabies Virus Mutant gD-Pass.

Authors:  Julia E Hölper; Finn Grey; John Kenneth Baillie; Tim Regan; Nicholas J Parkinson; Dirk Höper; Thiprampai Thamamongood; Martin Schwemmle; Katrin Pannhorst; Lisa Wendt; Thomas C Mettenleiter; Barbara G Klupp
Journal:  Viruses       Date:  2021-08-09       Impact factor: 5.048

Review 7.  Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development.

Authors:  Henriette Ebel; Tim Benecke; Benjamin Vollmer
Journal:  Viruses       Date:  2022-08-18       Impact factor: 5.818

8.  Role of Vesicle-Associated Membrane Protein-Associated Proteins (VAP) A and VAPB in Nuclear Egress of the Alphaherpesvirus Pseudorabies Virus.

Authors:  Anna D Dorsch; Julia E Hölper; Kati Franzke; Luca M Zaeck; Thomas C Mettenleiter; Barbara G Klupp
Journal:  Viruses       Date:  2021-06-10       Impact factor: 5.048

9.  In Vitro Viral Evolution Identifies a Critical Residue in the Alphaherpesvirus Fusion Glycoprotein B Ectodomain That Controls gH/gL-Independent Entry.

Authors:  Melina Vallbracht; Henriette Lötzsch; Barbara G Klupp; Walter Fuchs; Benjamin Vollmer; Kay Grünewald; Marija Backovic; Felix A Rey; Thomas C Mettenleiter
Journal:  mBio       Date:  2021-05-04       Impact factor: 7.867

10.  Identifying HSV-1 Inhibitors from Natural Compounds via Virtual Screening Targeting Surface Glycoprotein D.

Authors:  Jiadai Wu; Helen Power; Monica Miranda-Saksena; Peter Valtchev; Aaron Schindeler; Anthony L Cunningham; Fariba Dehghani
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.